Pranabananda Dutta

Pranabananda Dutta serves as an Assistant Professor in the College of Medicine at Charles R. Drew University of Medicine and Science, where his research centers on molecular oncology with emphasis on breast, lung, and prostate cancers. He investigates health disparities affecting African American and Hispanic populations through the lens of obesity, diabetes, hypertension, and genetic variations influencing cancer risk and progression.

His research program spans epigenetic regulation, STAT signaling pathways, and inflammatory cytokine networks in tumor microenvironments. Key interests include DNA methylation profiles in obese patients, CCL2/PARP1-driven cancer invasiveness, PD-L1 biomarker validation, and heterochromatin-modulating drugs like methotrexate. His work consistently addresses health inequities by examining how social determinants intersect with molecular mechanisms to worsen cancer outcomes in underserved communities.

Analysis of his 2019-2024 publications reveals three dominant trends: (1) Breast cancer mechanisms in minority populations, particularly triple-negative subtypes linked to obesity and inflammation; (2) Epigenetic drivers of tumor suppression involving STAT proteins and heterochromatin formation; (3) Translational exploration of drug repurposing (e.g., methotrexate) and novel targets like CARF in prostate cancer metastasis. His studies frequently employ genomic, transcriptomic, and epigenomic approaches to address health disparities.

Scientific awards: No honors, fellowships, or medals are documented in the provided materials.

While specific advising activities and grant details remain undisclosed in available sources, his publication record indicates active mentorship in cancer biology research. Multiple collaborative studies on breast cancer disparities and epigenetic mechanisms suggest involvement in team science, though formal grant listings are absent from the scraped content.

Lab and team structures are not explicitly described, but his research on tumor microenvironments, cytokine networks, and health disparities implies participation in multidisciplinary oncology initiatives at Charles R. Drew University, likely involving clinical collaborators focused on underserved patient populations in South Los Angeles.